The Defense Health Agency awarded Wayne State University $140,000 on December 15, 2026, under the Military Medical Research and Development program (CFDA 12.420) to support research on inducing ferroptosis through GPX4 inhibition as a novel therapeutic approach for esophageal cancer. The award is structured as a Project Grant with a period of performance through December 14, 2028, and performance takes place in Detroit, Michigan. Wayne State University's Sponsored Project Administration Division, doing business as Wayne State University Physician Group, serves as the recipient. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research to transform health care for Service Members and the American public through innovative research and investigation of medical solutions for battlefield needs.